Adam Brouillard
Cardiovascular Disease · Houston, TXNPI 1427578558
Payments from drug & device makers
Across 520 payments — averaging $73.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Silk Road Medical, Inc.$8K
- Edwards Lifesciences$3K
- Medtronic$3K
- Boston Scientific$2K
- Penumbra, Inc.$2K
- plus $8K from 36 others
Across 1 payment — averaging $149.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$149
What the payments were for
- Consulting fees$7,57520%
- Grants$2,0005%
- Travel & lodging$11,57730%
- Food & beverage$16,61743%
- Education$5932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$16,698
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$8,349
- ENROUTE Transcarotid Stent$8,349
- SUPERA$3,434
- Indigo System$1,402
- OPTIS$1,336
- ACCULINK$1,004
- FLOWTRIEVER CATHETER, S$1,002
- Perclose ProStyle$955
- Edwards SAPIEN 3 Transcatheter Heart Valve$848
- XACT$733
- JETi Peripheral Catheter$660
- AngioJet Ultra 5000A$625
- CT THROMBECTOMY SYSTEM KIT$620
- GLIDESHEATH SLENDER$476
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$425
- PERCLOSE PROGLIDE$404
- Torus Stent Graft System$388
- ENDOCROSS Device$388
- OPTIMIZER$274
How this compares
$38,363 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $16,102 |
| BrilintaTicagrelor | 14 | $9,833 |
| ClopidogrelClopidogrel Bisulfate | 49 | $1,280 |
| Atorvastatin Calcium | 51 | $1,005 |
| Rosuvastatin Calcium | 17 | $654 |
| Carvedilol | 26 | $613 |
| Metoprolol Succinate | 13 | $485 |
| Losartan Potassium | 17 | $442 |
| Amlodipine Besylate | 20 | $331 |
| Metoprolol Tartrate | 18 | $161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $336 | $16,10211 claims |
| AstraZenecaBrilinta | $119 | $9,83314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.